KCM
ALDX icon

Kingdon Capital Management’s Aldeyra Therapeutics ALDX Stock Holding History

Kingdon Capital Management’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.64M Buy
2,152,315
+302,315
+16% +$1.32M 0.4% 56
2025
Q4 		$9.58M Buy
1,850,000
+518,209
+39% +$2.66M 1.14% 40
2025
Q3 		$6.95M Hold
1,331,791
– – 0.86% 53
2025
Q2 		$5.1M Buy
1,331,791
+552,791
+71% +$1.43M 0.69% 54
2025
Q1 		$4.48M Buy
+779,000
New +$4.6M 0.47% 49

Other funds holding ALDX

KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Kingdon Capital Management's ALDX Position: Q1 2026 in Review

Kingdon Capital Management increased its Aldeyra Therapeutics (ALDX) stake by 16% in Q1 2026, buying an estimated $1.32M and bringing the position to 2,152,315 shares worth $3.64M. The position accounts for 0.4% of the portfolio, ranked #56.

Kingdon Capital Management first reported a position in ALDX in Q1 2025 and has held it in 5 quarters since. The position peaked at $9.58M in Q4 2025. 126 funds tracked by Wall St. Rank hold ALDX as of Q1 2026.

  • Kingdon Capital Management held 2,152,315 shares of Aldeyra Therapeutics worth $3.64M as of Q1 2026.
  • Kingdon Capital Management bought 302,315 Aldeyra Therapeutics shares in Q1 2026, an estimated $1.32M.
  • Aldeyra Therapeutics made up 0.4% of Kingdon Capital Management's portfolio in Q1 2026, its #56 holding.
  • Kingdon Capital Management first reported a position in Aldeyra Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • Kingdon Capital Management's Aldeyra Therapeutics position peaked at $9.58M in Q4 2025.
  • 126 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q1 2026.

Based on Kingdon Capital Management's 13F filing for Q1 2026, filed 15 May 2026.